Skanska announced that Pfizer has reduced the scope of work on its 25,000 square-meter biomanufacturing facility in Everett, Washington, USA, which Skanska previously was contracted to construct. The order reduction amounts to USD 49 million, about SEK 510 million, which will be deducted from the US order bookings for the first quarter 2024. The initial contract with Seagen, who recently was acquired by Pfizer, was worth USD 215 million, about SEK 2.2 billion, and was announced August 4, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
201.6 SEK | +1.61% | +5.08% | +10.56% |
02/05 | Skanska AB Announces Executive Appointments | CI |
29/04 | Skanska Receives SEK380 Million Residential Project in Czech Republic | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.56% | 7.65B | |
-1.06% | 69.18B | |
-3.89% | 56.54B | |
+23.67% | 39.07B | |
+12.47% | 31.2B | |
+7.57% | 28.05B | |
+16.37% | 20.96B | |
+74.25% | 17.64B | |
+25.86% | 17.27B | |
+13.67% | 15.16B |
- Stock Market
- Equities
- SKA B Stock
- News Skanska AB
- Skanska Announces Decreased Scope for Facility in Everett, Washington, USA, Worth USD 49 Million, About SEK 510 Million